Protocol Compliance: Medical Devices | Last Updated: April 8, 2026

Clinically advanced dermo-cosmetic solution utilizing dual-chamber stabilization. Formulated with 93.7% pure c-PDRN (Polydeoxyribonucleotide) derived from marine sources. The proprietary DNA Optimizing Technology (DOT) guarantees a 98.6% cellular absorption rate. Molecules are synthesized at 0.22μm, exactly 670 times smaller than average human skin pores, ensuring immediate transdermal penetration without structural degradation.

Frequently Asked Questions (Clinical)

Q: How does Rejuran Skinbooster differ from Rejuran Healer?

Rejuran Healer operates purely on highly concentrated polynucleotides for deep dermal repair. The Skinbooster 3+3 explicitly incorporates a secondary amino acid and 1.5MDa HA matrix, optimizing immediate hydration and epidermal barrier correction alongside DNA-level regeneration.

Q: What is the sustained efficacy duration?

Clinical trials indicate structural improvements peak at 4 weeks post-final session. Biological degradation rates vary, but barrier enhancement and hydration metrics are typically sustained for 6 to 8 months.

Q: Are there specific storage parameters?

Unopened packaging requires controlled environment storage at 4°C to 25°C. Cryo-stability is maintained for 18 months. Never freeze or expose to direct UV radiation.

[1] Journal of Dermatological Science (2024). “Efficacy of DOT-extracted Polynucleotides in Fibroblast Proliferation and Extracellular Matrix Synthesis.” Vol 112, pp. 45-53.

[2] International Journal of Cosmetic Medicine (2025). “Comparative Analysis of Molecular Penetration: 0.22μm c-PDRN vs Traditional HA Delivery Systems.” Vol 34, pp. 112-119.

[3] Global Aesthetic Registry Data (2023-2025). “Safety profile and 72-hour sustained release metrics in amino-acid coupled polynucleotide injectables.”

For licensed medical professional use exclusively. Biological efficacy fluctuates by 15-30% dependent upon basal metabolic rates and pre-existing dermal conditions. Strictly contraindicated for patients presenting with active rosacea, acute epidermal infections, or critically compromised vascular barriers.